Clinical case of immunotherapy treatment of a patient with triple-negative breast cancer

Triple negative breast cancer refers to a subgroup of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor type 2 (HER2). This makes them extremely insensitive to treatment with currently available drugs, including those that specifically target HER-2 or hormonal drugs. This type of cancer occupies 17% of the overall structure of breast cancer (1134 cases in the Republic of Kazakhstan in 2019), but is distinguished by the most unfavorable prognosis, aggressive course and rapid growth.The article describes the clinical case of patient, 38 years old, who in 2021 was diagnosed with left breast cancer St I (urT1cN0M0). G3.The given clinical example reflects how to achieve stabilization of the process during MTS in the liver with triple negative breast cancer.Keywords: triple negative breast cancer, immunotherapy, survival, treatment.